The present invention relates to a morphinan derivative that has an opioid κ receptor agonist effect and that is represented by general formula (I). (In the formula, R1 indicates a hydrogen atom, a C1-6 alkyl group that may have a substituent, or the like； R2 and R3 are the same or different and each indicate a hydrogen atom, a C1-6 alkyl group that may have a substituent, or the like； R4 and R5 are the same or different and each indicate a hydrogen atom, a C1-6 alkyl group that may have a substituent, or the like； R6 indicates a hydrogen atom, a C1-6 alkoxy group that may have a substituent, or the like； R7 indicates a hydrogen atom, a C1-6 alkyl group that may have a substituent, or the like； R8 and R9 are the same or different and each indicate a hydrogen atom, a C1-6 alkyl group that may have a substituent, or the like； R10 and R11 are the same or different and each indicate a hydrogen atom, a C1-6 alkyl group that may have a substituent, or the like； R12 and R13 are the same or different and each indicate a hydrogen atom or the like； R14 indicates a heteroaryl group that may have a substituent or the like； X indicates a nitrogen atom or the like； Y indicates C=O or the like； Z indicates an oxygen atom or the like； a double line consisting of a solid line and a broken line indicates a single bond or the like； m indicates an integer of 0-1； and n indicates an integer of 0-3.) The present invention also relates to a tautomer, a stereoisomer, or a pharmaceutically acceptable salt of said compound, or a solvate of said substances.La présente invention concerne un dérivé de morphinane qui a un effet agoniste du récepteur kappa opioïde et qui est représenté par la formule générale (I). (Dans la formule, R1 représente un atome d'hydrogène, un groupe alkyle en C1-6 qui peut avoir un substituant, ou similaire ； R2 et R3 sont identiques ou différents et représentent chacun un atome d'hydrogène, un groupe alkyle en C1-6 qui peut avoir un substituant, ou similaire ； R4 et R
